CClinicalTrials.gg
CompletedNCT03299543Updated Aug 29, 2018

Comparison Between Breath Acetone and Blood Beta-Hydroxybutyrate

An observational study in Ketosis, sponsored by Medamonitor. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-29.

Sponsored by Medamonitor · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
61
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Subjects will provide blood and breath samples to evaluate the relationship between breath acetone and two blood-bound species: beta-hydroxybutyrate and glucose. Subjects will be asked to provide breath and blood samples at a baseline visit and second optional visit. The two visits will be spaced approximately 3 hours apart.

Read the detailed description

The LEVL device (Medamonitor, Seattle, WA) provides users a method for assessing their own rate of fat metabolism. The LEVL device measures the concentration acetone in breath that the scientific literature has shown to correlate to the rate of fat metabolism.

Typically, the body uses glucose to meet its metabolic energy requirements. If needed, the body can shift from using glucose to using fat. Many different scenarios can cause this shift. Exercise can deplete accessible carbohydrate stores causing the body to use fats for energy production. Dietary changes that cause fat intake to increase and carbohydrate intake to decrease will alter metabolism to efficiently utilize the change in nutrients. In all of these scenarios, the body reduces it utilization of carbohydrates and, thus, shifts to using fats for energy production.

When the body uses fats as an energy substrate, some of these fat molecules are converted by the liver into acetoacetate, a ketone body. By enzymatic action, acetoacetate (AcAc) can be converted into beta-hydroxybutyrate (BOHB). The same enzyme can generate AcAc from BOHB. Additionally, acetoacetate can convert spontaneously into acetone which, due to its small size and highly water solubility, can readily appear in the breath.

Currently, measurement of BOHB in blood is the gold standard for assessing ketone body concentration, also known as ketosis. BOHB measurement requires an invasive finger puncture to obtain blood and a costly (\~$5 / test) assay. Because acetone (BrAce) is a sister ketone body to BOHB, breath acetone may be used to assess ketosis and replace the measurement of BOHB. Data in the scientific literature has shown BrAce to correlate with BOHB. Inferring BOHB concentrations from measurement of BrAce using LEVL is less invasive and is potentially less costly.

Reports have suggested that breath acetone is inversely correlated to blood sugar. However, others have suggested no relationship between the two species. If a relationship does exist, measurement of breath acetone could be used as a surrogate measure for blood sugar, a common assay used by individuals with diabetes.

In this study, subjects will provide blood and breath samples evaluate the relationship between breath acetone and two blood-bound species: BOHB and glucose. Subjects may be asked to provide breath and blood samples at two different times (i.e., visits) spaced approximately 3 hours apart. The second visit is not required for participation in the study (i.e., optional).

02

Conditions studied

  • Ketosis

Browse trials for

Keywords

  • beta-hydroxybutyrate
  • breath acetone
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Healthy individuals

Inclusion criteria

  1. Subject must complete the consent process

Exclusion criteria

Exclusion Criteria:

  1. Subjects with severe lung disease which would prevent them from providing a breath sample through a large bore tube (e.g., large drinking straw)
  2. Subjects with diabetes (Type 1 or Type 2)
  3. Subjects who are routinely exposed to paints, paint thinners, gasoline, varnishes, glues, dry cleaning solvents, or industrial cleaning products
  4. Daily smoker of cigarettes, e-cigarettes, or marijuana
  5. Abstain from alcohol over the prior 24 hours
  6. Refrain from consumption of large amounts of garlic
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
61 participants (actual)
Patient registry
No

Groups and cohorts

  • Healthy adults

    Healthy adults who are able to provide duplicate breath samples and pin-drop blood samples

    Device: LEVL (Medamonitor)

Interventions

  • DeviceLEVL (Medamonitor)

    Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone

05

What researchers measure

Primary outcomes

  1. Breath acetone concentration (ppm) will be compared against blood BOHB concentration (mM). The following methods may be used: summary statistics, plotting, and linear regression.

    Both individual and average group measurements will be compared

    Time frame: Through study completion, 4 months

Secondary outcomes

  1. Breath acetone concentration (ppm) will be compared against blood glucose concentration (mg/dL). The following methods may be used: summary statistics, plotting, and linear regression.

    Both individual and average group measurements will be compared

    Time frame: Through study completion, 4 months

  2. Blood glucose concentration (mg/dL) will be compared against blood BOHB concentration (mM). The following methods may be used: summary statistics, plotting, and linear regression.

    Both individual and average group measurements will be compared

    Time frame: Through study completion, 4 months

06

Study locations

1 site
  • Medamonitor, LLC
    Seattle, Washington 98119, United States
07

Registry details

Key details

Study ID
NCT03299543
Lead sponsor
Medamonitor
Responsible party
Sponsor
First posted
Oct 3, 2017
Start date
Sep 12, 2017
Primary completion
Feb 16, 2018
Completion
Feb 28, 2018
Last update
Aug 29, 2018

Study contacts

Joseph C Anderson, PhD
principal investigator · Medamonitor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion